



emulate

Protocol for Emulate Organ-Chips:

Assessment of Cleaved Caspase-3

April 8, 2021

EP211 v1.0

TITLE Assessment of Cleaved Caspase-3	DOCUMENT EP211	VERSION 1.0
	DATE 4-8-2021	PAGE 2 OF 2

Goals:	Key Steps:	Other Required Materials:
Assess cleaved Caspase 3 levels in Emulate Primary Colon Intestine-Chip epithelial cells lysates	<ul style="list-style-type: none"> Prepare all reagents, samples, and positive and negative control samples Run the assay Read the plate 	<ul style="list-style-type: none"> Cleaved/Total Caspase-3 Whole Cell Lysate Kit (Meso Scale Diagnostics, cat# K15140D) MSD Protein Lysis Buffer (cat# R60TX-3) Meso Scale Discovery plate reader Multi-channel P200 pipette, P20–P1000 pipettes and tips

Introduction

This protocol uses the Colon Intestine-Chip as a reference point aiming to the semi-quantitative assessment of the cleaved Caspase 3 levels under baseline conditions and upon basolateral stimulation with pro-inflammatory cytokines. These methods and assay conditions could change with a different Organ-Chip. Please reach out to [Emulate Field Science Support](#) for additional guidance.

Method

Sample type	Organ-Chip epithelial cells protein lysate See Emulate Protocol EP210 Protein Sample Lysing.
Recommended assay flow rate (Colon Intestine-Chip)	30 μ L/h
Recommended protein sample dilution (Colon Intestine-Chip)	Dilute samples in protein lysis buffer to a final concentration of 400 μ g/mL. Note: Cleaved Caspase-3 levels will change depending on cell injury status or based on donor-to-donor variability. Therefore, sample dilutions may need to be modified to accommodate different experimental conditions or cells from different donors.
Run assay as described on supplier site	https://www.mesoscale.com/en/products/cleaved-total-caspase-3-whole-cell-lysate-kit-k15140d/ Note: Store kit at 4°C immediately upon receipt.
Range of stimulation	IFN γ : 10-100 ng/mL (36h – 72h) IL-22: 1nM (24h – 72h)

© Emulate, Inc., 2021. All rights reserved.

Emulate® and the Emulate logo are registered trademarks of Emulate, Inc.

The technology disclosed in this document may be covered by one or more patents or patent applications owned by or licensed to Emulate, Inc. No license is granted herein. You are solely responsible for determining whether you have all intellectual property rights that are necessary for your intended use of Emulate products or protocols, and whether you are required to obtain any additional intellectual property rights from a third party. Further information is available by contacting Emulate.